Clinical Trial

Advanced Imaging to Assess the Effect of Immunosuppression on Progressive Fibrosis

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to investigate how immunosuppression treatment affects measurements of active collagen deposition using \[68Ga\]CBP8 positron emission tomography (PET) and tissue injury using dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) in individuals with non-idiopathic pulmonary fibrosis interstitial lung disease (non-IPF ILD).
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-05-02.
Trial Details
NCT Number NCT07572383
Lead Sponsor Peter Caravan
Collaborators: National Heart, Lung, and Blood Institute (NHLBI)
Conditions Interstitial Lung Disease, Pulmonary Fibrosis
Enrollment 15 participants
Start Date 2026-05-14
Primary Completion 2028-12-31 (estimated)
Study Completion 2028-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-07-14